Information Provided By:
Fly News Breaks for August 30, 2019
UBS, TD, NVO, ULTA
Aug 30, 2019 | 10:06 EDT
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Citi, to Neutral from Overweight at Piper Jaffray and Atlantic Equities, to Neutral from Outperform at Exane BNP Paribas, to Market Perform from Outperform at Wells Fargo, and to Equal Weight from Overweight at Morgan Stanley. 2. Toronto-Dominion (TD) downgraded to Market Perform from Outperform at BMO Capital with analyst Sohrab Movahedi saying he views the company's Q4 results as a "low-quality meet" and believes the stock's total return potential is now in line with other similarly rated banks. 3. Novo Nordisk (NVO) downgraded to Underperform from Hold at Jefferies with analyst Peter Welford saying he believes the shares at current levels are becoming expensive. 4. UBS (UBS) downgraded to Neutral from Outperform at Exane BNP Paribas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For ULTA;NVO;TD;UBS From the Last 2 Days
UBS
Mar 28, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
NVO
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.